Retroviral integration into host cell chromosomes was once thought to be random, but new evidence suggests that human immunodeficiency virus preferentially enters the neighborhood of activated genes.

Adeno-associated virus (AAV) vectors are currently being used in several clinical gene-therapy trials (see the NIH OBA Human Gene Transfer Clinical Trials Database); however, little is known about the ...